CITIUS ONCOLOGY, INC.
For the period ended Mar 31, 2026. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 31, 2026 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
CTOR$0.51+1.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · INDICATION
INDICATION
LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.